替雷利珠单抗用于接受透析的复发难治性多发性骨髓瘤患者。 - Suppr | 超能文献

相似文献

1

Teclistamab for relapsed refractory multiple myeloma patients on dialysis.替雷利珠单抗用于接受透析的复发难治性多发性骨髓瘤患者。

Br J Haematol. 2024 Nov;205(5):2077-2079. doi: 10.1111/bjh.19772. Epub 2024 Sep 14.

2

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.特卡昔单抗，一种 B 细胞成熟抗原 × CD3 双特异性抗体，用于治疗复发或难治性多发性骨髓瘤（MajesTEC-1）：一项多中心、开放标签、单臂、1 期研究。

Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.

3

Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。

N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.

4

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.在MajesTEC-1研究中接受替西妥单抗治疗复发/难治性多发性骨髓瘤患者的感染发生率、发生时间及管理

Cancer. 2024 Mar 15;130(6):886-900. doi: 10.1002/cncr.35107. Epub 2023 Nov 14.

5

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.在 Prospective LocoMMotion 研究中，三药暴露复发和/或难治性多发性骨髓瘤患者的真实世界临床实践中，替西罗莫司与现有治疗方案的疗效比较。

Adv Ther. 2023 May;40(5):2412-2425. doi: 10.1007/s12325-023-02480-7. Epub 2023 Mar 24.

6

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.在三药暴露复发/难治性多发性骨髓瘤中，特里斯他单抗与现实世界中医生治疗选择的比较疗效：LocoMMotion 和 MoMMent 研究。

Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.

7

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review.替西妥单抗作为复发多发性骨髓瘤心包积液的有效治疗方法：病例报告及文献综述

Case Rep Oncol. 2024 Sep 23;17(1):1063-1069. doi: 10.1159/000540979. eCollection 2024 Jan-Dec.

8

Teclistamab: First Approval.特卡昔单抗：首次批准。

Drugs. 2022 Nov;82(16):1613-1619. doi: 10.1007/s40265-022-01793-1.

9

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.特西珠单抗治疗复发/难治性多发性骨髓瘤患者的群体药代动力学和暴露-反应：MajesTEC-1 研究结果。

Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15.

10

Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.新型获批及即将面世的用于治疗复发/难治性多发性骨髓瘤的靶向 T 细胞的双特异性抗体。

J Oncol Pharm Pract. 2023 Apr;29(3):722-726. doi: 10.1177/10781552231154809. Epub 2023 Feb 12.

引用本文的文献

1

Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report.用替西妥单抗治疗的难治性多发性骨髓瘤年轻患者实现透析独立：一例报告

Oncol Lett. 2025 Aug 8;30(4):474. doi: 10.3892/ol.2025.15220. eCollection 2025 Oct.

2

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis.埃兰妥单抗用于伴有严重肾功能损害且需要血液透析的复发/难治性多发性骨髓瘤

Hematol Oncol. 2025 Jul;43(4):e70120. doi: 10.1002/hon.70120.

3

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.